Prothena Corporation plc: Q2 2014 Form 10-Q Summary
Business context and reporting period
Prothena is an Ireland-incorporated, clinical-stage biotechnology company developing antibody-based therapies for protein-misfolding and cell-adhesion diseases. Its principal candidates include NEOD001 for amyloidosis, PRX002 for Parkinson’s disease and related synucleinopathies, and PRX003 for inflammatory diseases and cancers. This unaudited Form 10-Q covers the three and six months ended June 30, 2014, with comparisons to the same periods in 2013.
Financial performance and position
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Total revenue | $15.1 million | $0.2 million | $47.4 million | $0.3 million |
| Collaboration revenue | $15.0 million | — | $47.1 million | — |
| Operating expenses | $13.6 million | $11.4 million | $27.8 million | $20.5 million |
| Income (loss) from operations | $1.6 million | $(11.2) million | $19.6 million | $(20.2) million |
| Net income (loss) | $1.3 million | $(11.3) million | $19.1 million | $(20.3) million |
| Diluted EPS | $0.06 | $(0.64) | $0.83 | $(1.15) |
- Q2 operating margin was approximately 10.4% and net margin approximately 8.5%; six-month operating margin was approximately 41.4% and net margin approximately 40.4%. These margins were primarily driven by Roche collaboration payments and are not indicative of recurring commercial profitability.
- Research and development expense increased 6% year over year in Q2 to $8.6 million and 27% for the six months to $18.0 million. General and administrative expense increased 54% in Q2 to $4.9 million and 53% for the six months to $9.8 million.
- Six-month operating cash flow was $24.1 million, compared with $(12.0) million in the prior-year period. Investing cash flow was $(0.4) million, primarily for property and equipment.
- Financing cash flow was $103.4 million, principally from the June public offering. Cash and cash equivalents increased $127.2 million to $303.9 million at June 30, 2014, including $274.8 million in money-market funds.
- Working capital was $295.7 million. Total liabilities were $13.3 million and shareholders’ equity was $298.4 million. The filing does not report debt or borrowings; liabilities primarily comprise operating accruals, taxes and deferred rent.
- Shares outstanding were 26.7 million at June 30, 2014 and 27.4 million as of July 25, 2014.
Material changes versus the prior comparable period
- Roche’s license agreement became effective in January 2014. Prothena recognized a $30.0 million upfront payment in the first quarter and a $15.0 million clinical milestone payment in the second quarter after initiation of the PRX002 Phase 1 study.
- Of the $15.0 million milestone, $13.3 million was recorded as collaboration revenue and $1.7 million as an offset to R&D expense. Roche also provided development-cost reimbursements and research-service funding.
- Prothena completed a June offering of 4.75 million ordinary shares at $22.50 per share, generating approximately $102.5 million in net proceeds. In July 2014, underwriters purchased an additional 712,500 shares, generating approximately $14.9 million in additional net proceeds.
- R&D spending shifted toward PRX002 clinical development, manufacturing and related Roche cost-sharing activities, while NEOD001 spending increased in anticipation of a Phase 2/3 program. G&A growth reflected higher personnel, legal and public-company costs.
- Share-based compensation increased to $2.8 million for the six months from $1.1 million in the prior-year period. Approximately $18.1 million of unearned compensation remained to be recognized through 2017.
Guidance, outlook, commentary and risks
- Management believes cash and cash equivalents are sufficient to fund obligations for at least the next twelve months, but expects substantial losses for the foreseeable future and anticipates needing additional capital to complete development programs.
- Management expects 2014 R&D and G&A expenses to increase, driven by PRX003 manufacturing and toxicology work, the anticipated NEOD001 Phase 2/3 trial, PRX002 clinical development and expansion of public-company infrastructure. No quantified earnings or expense guidance was provided.
- Interim NEOD001 results were described as supporting advancement into a Phase 2/3 study later in 2014. Prothena and Roche initiated a PRX002 Phase 1 study in April; a multiple-ascending-dose Phase 1 study in Parkinson’s patients was initiated in July 2014.
- Under the Roche agreement, Roche funds 100% of research activities. U.S. development and commercialization costs and profits for opted-in products are allocated 70% to Roche and 30% to Prothena. Roche may terminate the agreement after the first anniversary subject to notice provisions, creating substantial collaboration and revenue risk.
- Potential Roche consideration includes up to $380 million in development, regulatory and first-commercial-sale milestones, up to $175 million in ex-U.S. commercial milestones, and tiered royalties. These amounts are contingent and are not guaranteed.
- Key risks include clinical-trial failure or delay, regulatory rejection, uncertain commercialization and reimbursement, dependence on Roche and third-party clinical and manufacturing providers, intellectual-property challenges, need for additional financing, dilution from future equity issuance, foreign-exchange exposure and loss of key personnel.
- Contractual obligations included $12.7 million of operating leases, $4.2 million of supplier purchase commitments and $1.2 million under license agreements. Future Roche cost-sharing obligations were not quantifiable.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and effective disclosure controls as of June 30, 2014.
Important facts for investors to verify
- Confirm the accounting treatment, timing and remaining recognition of Roche’s upfront, milestone and reimbursement payments, including the revised $35.6 million allocated license value.
- Assess how much of the $303.9 million cash balance represents unrestricted operating liquidity and incorporate the additional $14.9 million July offering proceeds.
- Monitor PRX002 and NEOD001 clinical results, trial enrollment, safety findings, regulatory milestones and the timing and cost of planned studies.
- Review Roche’s termination, opt-out, cost-sharing and profit-sharing rights and the conditions for future milestones and royalties.
- Evaluate projected cash burn, expected future losses, additional financing needs and potential shareholder dilution.
- Assess reliance on Boehringer Ingelheim and other third parties for clinical drug supply, manufacturing and trial execution.